Pharmacological treatment

Interventions for fatigue in Parkinson’s disease

Abstract Background Factors contributing to subjective fatigue in people with idiopathic Parkinson’s disease (PD) are not well known. This makes it difficult to manage fatigue effectively in PD. Objectives To evaluate the effects of pharmacological and non-pharmacological interventions, compared to an inactive control intervention, on subjective fatigue in people with PD. Search methods We searched […]

Share

Creatine for Parkinson’s disease

Abstract Background Parkinson’s disease is one of the most common neurodegenerative disorders and mitochondrial dysfunction plays an important role in its pathogenesis. Creatine is effective in improving mitochondrial function. It may therefore be useful for slowing the progression of Parkinson’s disease. Objectives To assess the efficacy and safety of creatine used alone or as an […]

Share

Anti-hypertensive drugs as disease-modifying agents for Parkinson’s disease: evidence from observational studies and clinical trials

Abstract Background Current treatment for Parkinson’s disease (PD) is focused on relieving symptoms, at present there is nothing that is widely accepted to halt or slow disease progression. Potential neuroprotective or disease modifying agents have been identified from preclinical studies. One such group of compounds are anti-hypertensive drugs. Objectives 1) Do anti-hypertensive drugs prevent the onset […]

Share

Amantadine for dyskinesia in Parkinson’s disease

Abstract Background Abnormal involuntary movements known as dyskinesias are amongst the most disabling side-effects of levodopa therapy. It is thought that amantadine, an NMDA-receptor antagonist, may reduce dyskinesias in patients with Parkinson’s disease without worsening Parkinsonian symptoms. Objectives To compare the efficacy and safety of adjuvant amantadine therapy versus placebo in treating dyskinesia in patients […]

Share

Amantadine in Parkinson’s Diseas

Abstract Background Although levodopa is the most common drug prescribed to relieve the symptoms of Parkinson’s disease it is associated with motor and psychiatric side-effects. Consequently, interest has turned to alternative drugs with improved side-effect profiles to replace or augment levodopa. Amantadine, originally used as an antiviral drug, has been shown to improve the symptoms […]

Share

Beta-blocker therapy for tremor in Parkinson’s disease

Abstract Background The tremor of Parkinson’s disease can cause considerable disability for the individual concerned. Traditional antiparkinsonian therapies such as levodopa have only a minor effect on tremor. Beta-blockers are used to attenuate other forms of tremor such as Essential Tremor or the tremor associated with anxiety. It is thought that beta-blockers may be of […]

Share

Anticholinergics for symptomatic management of Parkinson´s disease

Abstract Background Anticholinergics were the first drugs available for the symptomatic treatment of Parkinson´s disease and they are still widely used today, both as monotherapy and as part of combination regimes. They are commonly believed to be associated with a less favourable side effect profile than other antiparkinsonian drugs, in particular with respect to neuropsychiatric […]

Share
  • The review abstracts published on this site are the property of John Wiley & Sons, Ltd., and of the Cochrane Review Groups that have produced the reviews.
Share
Share